Assert-IQ vs Tempus ECG-AF

Assert-IQ offers long-term, continuous remote monitoring with a patient activator for symptom logging, providing a largely passive and hands-off experience for both patients and clinicians after the initial minimally invasive insertion. This continuous data stream and proactive alerts can simplify long-term management of suspected heart rhythm disorders. Tempus ECG-AF, while integrating with existing systems, provides a single-point analysis that requires further clinical action.

Assert-IQ provides direct, continuous cardiac monitoring for up to six years, offering comprehensive data for the diagnosis and ongoing management of suspected arrhythmias. This long-term, real-time data collection is crucial for detecting intermittent and elusive heart rhythm disorders. Tempus ECG-AF, while valuable, offers a predictive risk assessment for future AF based on a single ECG, which is a different type of clinical utility compared to direct, continuous diagnostic and management data.

Tempus ECG-AF offers clear financial transparency by explicitly mentioning CMS reimbursement availability (CPT 0764T and CPT 0765T to APC 5734) with a specified Medicare rate. This provides a clear pathway for healthcare providers to understand and integrate the cost and revenue potential. Assert-IQ only states 'enterprise' pricing and requires direct contact for institutional pricing, lacking public transparency on cost or reimbursement.

Tempus ECG-AF is explicitly designed as a software solution integrated into healthcare facility systems and is compatible with FDA-authorized resting 12-lead ECGs from major vendors like GE Medical Systems and Philips Medical Systems. It also explicitly states having a Business Associate Agreement (BAA). Assert-IQ, while targeting large health systems and offering hybrid deployment and data export, does not mention API availability or the same level of explicit integration with existing diagnostic equipment.

Tempus ECG-AF demonstrates significant innovation by applying an AI-based algorithm to standard 12-lead ECG recordings to predict the risk of developing atrial fibrillation within 12 months in a specific patient population. This represents a novel use of existing diagnostic data for proactive, predictive medicine, trained on a massive dataset of over 1.5 million ECGs. Assert-IQ, while an advanced insertable cardiac monitor with extended battery life and enhanced features, builds upon an existing technology.

Abbott Medical, as a large and established medical device company, has a long history of providing comprehensive support and documentation for its products, including patient and clinician guides for Assert-IQ. While Tempus AI offers support for its solutions, the extensive and mature support infrastructure of a company like Abbott for a medical device typically provides a higher degree of readily available and detailed documentation and support channels.